This article is part of the supplement: VIII Madrid Breast Cancer Conference: Latest Advances in Breast Cancer
Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
Breast Cancer Research 2009, 11(Suppl 1):P29 doi:10.1186/bcr2312
No comments have yet been made on this article.